Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - First administration to humans
Status
Authorised, recruitment pending
Participants planned
36
Countries
1
Sites
1
Wound healing
Key facts
- Sponsor
- Ilya Pharma AB (publ)
- Participant type
- Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Not possible to specify
- Decision date (initial)
- 2024-11-26
- Transition trial
- Yes
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
External identifiers
- EU CT number
- 2024-518698-32-00
- EudraCT number
- 2019-000680-24
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Wound healing
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Ilya Pharma AB (publ)
- Sponsor organisation
- Ilya Pharma AB (publ)
- Address
- Dag Hammarskjolds Vag 30, Uppsala Domkyrkofors. Uppsala Domkyrkofors.
- City
- Uppsala
- Postcode
- 752 37
- Country
- Sweden
Scientific contact point
- Organisation
- Ilya Pharma AB (publ)
- Contact name
- Evelina Vågesjö
Public contact point
- Organisation
- Ilya Pharma AB (publ)
- Contact name
- Evelina Vågesjö
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Sweden | Authorised, recruitment pending | 36 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2024-10-28 | Sweden | Acceptable 2024-11-26
|
2024-11-26 |